Edward T. Mathers Acquires 500,000 Shares of MBX Biosciences, Inc. (NYSE:MBX) Stock

MBX Biosciences, Inc. (NYSE:MBX) Director Edward T. Mathers acquired 500,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $8,000,000.00. Following the completion of the transaction, the director now directly owns 3,614,486 shares of the company’s stock, valued at $57,831,776. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

MBX Biosciences Price Performance

NYSE:MBX opened at $21.50 on Wednesday. MBX Biosciences, Inc. has a 52 week low of $20.51 and a 52 week high of $26.08.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.